Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Evotec SE
  6. News
  7. Summary
    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 05/14 03:59:55 pm
33.83 EUR   +0.56%
05/12EVOTEC  : Deutsche Bank sticks Neutral
MD
05/11EVOTEC  : Receives a Buy rating from Warburg Research
MD
05/11EVOTEC  : Baader Bank reaffirms its Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

PRESS RELEASE: Evotec and the GCKD study enter into strategic collaboration to build a unique molecular patient database

05/04/2021 | 01:32am EDT
DGAP-News: Evotec SE / Key word(s): Miscellaneous 
Evotec and the GCKD study enter into strategic collaboration to build a unique molecular patient database 
2021-05-04 / 07:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
  . BIOSPECIMENS FROM >5,000 CKD (CHRONIC KIDNEY DISEASE) PATIENTS FROM THE GCKD COHORT STUDY WILL BE SCREENED AND 
    ANALYSED USING EVOTEC'S EVOPANOMICS AND EVOPANHUNTER PLATFORMS 
  . THE GENERATION OF LONGITUDINAL DATA FOR THOUSANDS OF CKD PATIENTS WILL RESULT IN AN UNPRECEDENTED MOLECULAR PATIENT 
    DATABASE 
  . THE STRATEGIC COLLABORATION PROVIDES UNIQUE OPPORTUNITIES TO DEEPEN THE UNDERSTANDING OF DISEASE MECHANISMS, 
    PROGRESSION AND POTENTIAL COMPLICATIONS 
Hamburg and Erlangen, Germany, 04 May 2021: 
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the University Hospital Erlangen today 
announced a partnership regarding molecular analyses of biospecimens from the German Chronic Kidney Disease ("GCKD") 
cohort study. Under the agreement, the research team will make use of Evotec's proprietary EVOpanOmics and EVOpanHunter 
platforms to facilitate deep molecular profiling of patient samples. The Evotec platforms combine enhanced throughput 
proteomics, high-throughput transcriptomics and integrated data analysis. 
Initiated in 2009, GCKD was designed to be the world's largest cohort study on chronic kidney disease. Scientists from 
eleven universities work together with more than 150 practicing nephrologists to monitor more than 5,000 patients with 
CKD with biospecimens being taken and supporting interviews being conducted multiple times during the interval. Evotec 
will also financially support GCKD, which will enable the extension of this important cohort study beyond the initial 
term of 10 years, allowing future follow-up visits and additional sample analysis. 
The multi-omics analysis of the biospecimens from the GCKD cohort study is expected to lead to a deeper understanding 
of different kidney disease etiologies, their respective disease mechanisms, progression and potential complications. 
Together with Evotec's existing molecular patient database, this systematic integrated exploitation of the GCKD biobank 
will open the door to novel starting points for drug discovery and the identification of biomarkers, enabling precision 
medicine approaches for highly effective treatment options for clearly defined patient populations. 
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We continue to work towards our goal to build a 
highly comprehensive molecular patient database. This collaboration is a major step forward towards this goal and we 
are very excited about the opportunity to work with this unique network. The GCKD cohort not only complements and 
expands our already leading kidney disease data base with well-documented long-term survey of CKD patients and 
corresponding patient samples. The more comprehensive the data base, the more impactful it will be in re-defining 
patient populations according to disease mechanisms rather than symptoms, identify suitable molecular targets for 
intervention and stratify patient populations for clinical trials." 
Prof. Dr Kai-Uwe Eckardt, Director of the Department of Nephrology and Medical Intensive Care at the Charité - 
Universitätsmedizin Berlin, and Principal Investigator of the GCKD Study, said: "CKD is a severe health problem that 
affects 10% of the population. The underlying mechanisms are complex and strong efforts are urgently needed to better 
understand this complexity. We are very excited to enter this collaboration with Evotec, which creates novel synergies 
and provides the prospect for innovative diagnostic and therapeutic approaches that can be translated into patient 
care." 
Prof. Dr Anna Köttgen, Head of the Institute of Genetic Epidemiology at the University of Freiburg, and Member of the 
GCKD Steering Committee added: "We are looking forward to expand the spectrum of molecular analyses in this cohort, 
which will greatly facilitate the discovery of robust associations between complex molecular phenotypes and clinical 
outcomes." 
"One of the challenges in studying CKD is the gradual decline of kidney function that may eventually lead to kidney 
failure. The GCKD study is unique as a long-term observational study and its extension will further increase the value 
of this huge research project," added Prof. Dr Mario Schiffer, Director of the Department of Nephrology and 
Hypertension at the Friedrich-Alexander-Universität Erlangen-Nürnberg, and also Member of the GCKD Steering Committee. 
About EVOpanOmics / EVOpanHunter 
EVOpanOmics and EVOpanHunter are two of the building blocks of Evotec's strategic framework, Action Plan 2025: "the 
data-driven R&D Autobahn to Cures". EVOpanOmics involves the innovative use of genomics, transcriptomics, proteomics, 
and phenotypic data in an integrated fashion. Evotec has established high-throughput transcriptomics and proteomics 
technologies, which can be used as unbiased read-outs in drug discovery and development. EVOpanHunter is Evotec's 
proprietary, integrated, user-centred bioinformatics platform which facilitates the analysis of PanOmics data 
integrated with other metadata sets. Evotec's proprietary platforms The combination of EVOpanOmics and EVOpanHunter on 
an integrated drug discovery and development platform is a game changer for data-driven approaches to highly effective 
personalised medicine. 
ABOUT EVOTEC SE 
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative 
product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and 
venture capitalists. We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and 
integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the 
industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has 
established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies 
as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and 
complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare 
diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned 
product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple 
long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo 
Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us 
on Twitter @Evotec. 
FORWARD-LOOKING STATEMENTS 
Information set forth in this press release contains forward-looking statements, which involve a number of risks and 
uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this 
press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of 
risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ 
materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or 
undertaking to release publicly any updates or revisions to any such statements to reflect any change in our 
expectations or any change in events, conditions or circumstances on which any such statement is based. 
Media Contact Evotec SE: 
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, 
gabriele.hansen@evotec.com 
IR Contact Evotec SE: 
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com 
=---------------------------------------------------------------------------------------------------------------------- 
2021-05-04 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Evotec SE 
              Manfred Eigen Campus / Essener Bogen 7 
              22419 Hamburg 
              Germany 
Phone:        +49 (0)40 560 81-0 
Fax:          +49 (0)40 560 81-222 
E-mail:       info@evotec.com 
Internet:     www.evotec.com 
ISIN:         DE0005664809 
WKN:          566480 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1191997 
 
End of News   DGAP News Service 
=------------ 

1191997 2021-05-04

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1191997&application_name=news 
 

(END) Dow Jones Newswires

May 04, 2021 01:31 ET (05:31 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG -0.04% 57.06 Delayed Quote.18.49%
CKD CORPORATION 6.79% 2297 End-of-day quote.4.03%
DJ INDUSTRIAL 1.06% 34382.13 Delayed Quote.9.74%
EVOTEC SE 0.33% 33.75 Delayed Quote.11.46%
MDAX 1.41% 32141.17 Delayed Quote.4.37%
NOVARTIS AG 0.55% 80.49 Delayed Quote.-4.30%
NOVO NORDISK A/S 2.92% 478.85 Delayed Quote.12.23%
PFIZER, INC. -0.20% 40.02 Delayed Quote.8.94%
SANOFI 0.14% 86.72 Real-time Quote.10.19%
TECDAX 1.32% 3327.8 Delayed Quote.3.58%
UCB 0.57% 77.82 Real-time Quote.-7.88%
All news about EVOTEC SE
05/12EVOTEC  : Deutsche Bank sticks Neutral
MD
05/11EVOTEC  : Receives a Buy rating from Warburg Research
MD
05/11EVOTEC  : Baader Bank reaffirms its Buy rating
MD
05/11EVOTEC  : RBC takes a positive view
MD
05/11EVOTEC  : reports results for the first quarter 2021 and provides corporate upda..
PU
05/11PRESS RELEASE  : Evotec se reports results for the -2-
DJ
05/11PRESS RELEASE : Evotec se reports results for the first quarter 2021 and provide..
DJ
05/11EVOTEC  : Reports results for the first quarter 2021 and provides corporate upda..
EQ
05/07EVOTEC  : launches 'beLAB1407' to accelerate translational research from the UK'..
AQ
05/07EVOTEC  : Buy rating from Warburg Research
MD
More news
Financials
Sales 2021 556 M 676 M 676 M
Net income 2021 39,3 M 47,7 M 47,7 M
Net cash 2021 1,33 M 1,62 M 1,62 M
P/E ratio 2021 132x
Yield 2021 -
Capitalization 5 524 M 6 704 M 6 709 M
EV / Sales 2021 9,92x
EV / Sales 2022 8,58x
Nbr of Employees 3 735
Free-Float 84,4%
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 34,61 €
Last Close Price 33,75 €
Spread / Highest target 18,5%
Spread / Average Target 2,55%
Spread / Lowest Target -12,6%
EPS Revisions
Managers and Directors
NameTitle
Werner Lanthaler Chief Executive Officer
Enno Spillner Chief Financial Officer
Wolfgang Plischke Chairman-Supervisory Board
Cord E. Dohrmann Chief Scientific Officer
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC SE11.46%6 647
MODERNA, INC.43.46%60 177
LONZA GROUP AG-1.83%45 717
IQVIA HOLDINGS INC.28.18%44 017
CELLTRION, INC.-24.65%31 985
SEAGEN INC.-17.37%26 262